Browsing byAuthorZang, D. Y.

Jump to:
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 1 to 6 of 6

Issue DateTitleAuthor(s)Type
2017CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB문영철Meeting Abstract
2017COMPARISON OF MOLECULAR KINETICS AFTER THE FIRST AND SECOND IMATINIB DISCONTINUATION: RESULTS FROM THE KID STUDY문영철Meeting Abstract
2017EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA문영철Meeting Abstract
2015PREDICTIVE FACTORS FOR TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH IMATINIB-TREATED, UNDETECTABLE MOLECULAR RESIDUAL DISEASE: RESULTS FROM THE KID STUDY문영철Meeting Abstract
2006The intention to treat analysis of the different post remission therapy modalities in AML patients with the "Intermediate Risk Group (IPG)" based on cytogenetics.성주명; 문영철Meeting Abstract
2017VERY EARLY MOLECULAR RESPONSE (VEMR) WITH FRONTLINE DASATINIB TREATMENT IS A STRONG PREDICTOR OF LONG-TERM BCR-ABL1 TRANSCRIPT LEVELS IN CHRONIC MYELOID LEUKEMIA PATIENTS: PCR-DEPTH STUDY문영철Meeting Abstract

BROWSE